GB2102287B - Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia. - Google Patents

Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia.

Info

Publication number
GB2102287B
GB2102287B GB08213407A GB8213407A GB2102287B GB 2102287 B GB2102287 B GB 2102287B GB 08213407 A GB08213407 A GB 08213407A GB 8213407 A GB8213407 A GB 8213407A GB 2102287 B GB2102287 B GB 2102287B
Authority
GB
United Kingdom
Prior art keywords
aromatase
treatment
prostatic hyperplasia
antiandrogens
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08213407A
Other languages
English (en)
Other versions
GB2102287A (en
Inventor
Hans-Udo Schweikert
Ulf Tunn
Friedmund Neumann
Theodor Senge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of GB2102287A publication Critical patent/GB2102287A/en
Application granted granted Critical
Publication of GB2102287B publication Critical patent/GB2102287B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GB08213407A 1981-05-22 1982-05-10 Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia. Expired GB2102287B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813121152 DE3121152A1 (de) 1981-05-22 1981-05-22 "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"

Publications (2)

Publication Number Publication Date
GB2102287A GB2102287A (en) 1983-02-02
GB2102287B true GB2102287B (en) 1985-02-27

Family

ID=6133382

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08213407A Expired GB2102287B (en) 1981-05-22 1982-05-10 Use of aromatase-inhibitors with antiandrogens for treatment of prostatic hyperplasia.

Country Status (15)

Country Link
US (1) US4598072A (enExample)
JP (1) JPS57193412A (enExample)
AU (1) AU563785B2 (enExample)
BE (1) BE890522A (enExample)
CA (1) CA1186998A (enExample)
CH (1) CH648211A5 (enExample)
DE (1) DE3121152A1 (enExample)
DK (1) DK354881A (enExample)
FR (1) FR2506158B1 (enExample)
GB (1) GB2102287B (enExample)
IT (1) IT1139175B (enExample)
LU (1) LU83545A1 (enExample)
NL (1) NL8103875A (enExample)
SE (1) SE463074B (enExample)
ZA (1) ZA823501B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3607651A1 (de) * 1986-03-06 1987-09-10 Schering Ag Kombination von aromatasehemmer und testosteron-5(alpha)-reduktase-hemmer
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
US5595985A (en) 1989-03-10 1997-01-21 Endorecherche Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5364847A (en) * 1989-03-10 1994-11-15 Endorecherche Inhibitors of sex steroid biosynthesis and methods for their production and use
US5372996A (en) * 1989-03-10 1994-12-13 Endorecherche, Inc. Method of treatment of androgen-related diseases
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
CA2062973C (en) * 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
DE4001060A1 (de) * 1990-01-16 1991-07-18 Kanoldt Arzneimittel Gmbh Verwendung einer ungesaettigten fettsaeure oder ihrer derivate in der human- und veterinaermedizin und zur herstellung einer arzneimittelzubereitung
KR950701527A (ko) * 1992-05-21 1995-04-28 라브리 페르낭 테스토스테론 5α 환원효소 활성 저해제(INHIBITORS OF TESTOSTERONE 5α-REDUCTASE ACTIVITY)
GB2278054A (en) * 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
MXPA00008868A (es) * 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia
GB0012293D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
US7001911B2 (en) 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0016426D0 (en) * 2000-07-05 2000-08-23 Astrazeneca Ab Pharmaceutical combination
AU2001271162A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
AU6800101A (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and anastrozole for providing an antiandrogenic effect and aromatase inhibition
EP1854798A3 (en) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6953679B2 (en) 2000-09-19 2005-10-11 Bristol-Myers Squibb Company Method for the preparation of fused heterocyclic succinimide compounds and analogs thereof
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6607755B2 (en) * 2001-06-21 2003-08-19 Michael Donald Farley Anti-aromatase pharmaceutical composition for controlling testosterone/estrone ratios
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US7087636B2 (en) * 2001-12-19 2006-08-08 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1641458A2 (en) 2002-12-27 2006-04-05 Schering Aktiengesellschaft Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
DK2060300T3 (da) * 2007-11-13 2015-06-22 Curadis Gmbh C-19-steroider til terapeutiske anvendelser
JP2012515184A (ja) * 2009-01-14 2012-07-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 大腸がんの治療方法
PT2811833E (pt) 2012-02-06 2015-12-07 William L Pridgen Associação de famciclovir e celecoxib para síndromes somáticas funcionais
EP2762135A1 (en) * 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JP2017515800A (ja) * 2014-04-08 2017-06-15 ザ・メソジスト・ホスピタル ｉＮＯＳ阻害組成物および乳がん治療薬としてのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3449494A (en) * 1966-09-29 1969-06-10 Squibb & Sons Inc Anti-inflammatory compositions containing a corticoidal steroid and a testololactone
US4055641A (en) * 1976-05-10 1977-10-25 Richardson-Merrell Inc. Method of treating benign prostatic hypertrophy
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
DE3362176D1 (en) * 1982-07-14 1986-03-27 Akzo Nv Novel 19-thio-androstane derivatives

Also Published As

Publication number Publication date
JPS57193412A (en) 1982-11-27
GB2102287A (en) 1983-02-02
US4598072A (en) 1986-07-01
IT8123988A0 (it) 1981-09-16
NL8103875A (nl) 1982-12-16
AU563785B2 (en) 1987-07-23
IT1139175B (it) 1986-09-24
BE890522A (fr) 1982-03-29
AU8407582A (en) 1982-11-25
JPH0150207B2 (enExample) 1989-10-27
ZA823501B (en) 1983-03-30
CA1186998A (en) 1985-05-14
FR2506158B1 (fr) 1986-05-09
LU83545A1 (de) 1981-12-01
SE463074B (sv) 1990-10-08
DE3121152C2 (enExample) 1991-02-07
DE3121152A1 (de) 1982-12-09
SE8104624L (sv) 1982-11-23
DK354881A (da) 1982-11-23
FR2506158A1 (fr) 1982-11-26
CH648211A5 (de) 1985-03-15

Similar Documents

Publication Publication Date Title
JPS57193412A (en) Prevention of prostatic hyperplasia and therapeutical drug
GB2100601B (en) An aromatase-inhibitor for use in a method of prophylaxis and/or of treatment by therapy of prostatic hyperplasia, and pharmaceutical preparations suitable for such a use.
ZA853697B (en) Derivatives of glycerophosphocholine and glycerophospho-ethanolamine,their preparation and their use
NO813192L (no) Fremgangsmaate til kjemisk behandling av en superlegering med hoeyt wolframinnhold, samt etsemiddel til utfoerelse av fremgangsmaaten
ZA889699B (en) Use of polysulfated heparins
ZA906544B (en) 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
DE3569075D1 (en) Method and compositions for use in the treatment of fireblight
DE3468212D1 (en) Monohydroxy-benzoyl peroxide and compositions for treating acne
HU9201045D0 (en) Combined preparation with antitrombotic effect
EP0200156A3 (en) Use of an aqueous solution of a chlorite matrix for treating tumours
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
FI823817A7 (fi) Nitroimidatsoliyhdisteitä ja näppyjen hoidossa käyttökelpoisia seoksia.
DE3373978D1 (en) Composition for the care or treatment of the human skin
GR860020B (en) Process for the treatment of biomass with steam product thereby obtained and its use and reactor
DE3665126D1 (en) Preparation on the basis of a mixture
EP0213072A3 (en) Treatment of chronic imflammatory disease
JPS53113025A (en) Proliferation inhibitor for microorganisms
IL72467A0 (en) New 1,2-diaryl-3-azolylpropane derivatives,their preparation and their use as agents for the treatment of plants
GR3029726T3 (en) Use of a therapeutic compound for the treatment of bronchitis
ZA845618B (en) New 1,2-diaryl-3-azolylpropane derivatives,their preparation and their use as agents for the treatment of plants
IL65774A0 (en) Citrate of naphthylhydrofuryl and its therapeutical use
ZA884315B (en) Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epostane type
ZA8664B (en) Process for the treatment of biomass with steam,product thereby obtained and its use and reactor
JPS57134416A (en) Acne treatment and therapeutical composition
JPS52137628A (en) Transporting method and tool for transformer associated with noise prevention wall

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19940510